Clinical Trial Update: A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and pharmacokinetics of ABBV-221 in adults with advanced solid tumors likely to overexpress EGFR was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Glioblastoma
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• ABBV-221

Snippet

Sponsor: AbbVie | Conditions: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED